Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Oktober 2024 10:31 ET | Quelle: Compass Therapeutics

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
10. September 2020 05:46 ET | Quelle: ImCheck Therapeutics SAS

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 Company Receives FDA Approval for US IND ...
20. März 2018 07:00 ET | Quelle: Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs

LONDON, Ontario and BOSTON, March 20, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture:COT) (OTCQB:COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company...
29. Juli 2015 18:20 ET | Quelle: JayMac Pharmaceuticals

EnLyte Monotherapy Reduces Toxic Homocysteine in Patients With MTHFR Polymorphism: Breakthrough Study Shows Significant Reduction In Toxic Amino Acid Linked To Hundreds Of Diseases

SUNSET, La., July 29, 2015 (GLOBE NEWSWIRE) -- A new study shows patients with the MTHFR C677T/A1298C enzyme polymorphism significantly benefit from reduced B vitamin therapy, marketed under the...